drugset / Trial / NCT00437359

Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer

NCT00437359

Phase 2 Terminated 240 enrolled Japan Breast Cancer Research Network
RandomizedParallel-groupOpen-labelTreatment

Summary

To investigate the benefit of postoperative adjuvant therapy using sequential administration of the hormone, toremifene citrate (TOR) or anastrozole (ANA), after chemotherapy in breast cancer.

Timeline

Start
2007-05
Primary completion
2017-05
Completion
2020-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 1 mg Oral
Subject Toremifene Small molecule 40 mg Oral

Indications